6/12
03:45 pm
tvgn
Tevogen Bio Set to Join Russell 3000® Index
Low
Report
Tevogen Bio Set to Join Russell 3000® Index
6/11
03:45 pm
tvgn
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts [Yahoo! Finance]
Low
Report
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts [Yahoo! Finance]
6/11
03:30 pm
tvgn
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
Low
Report
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
6/7
03:32 pm
tvgn
CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event
Low
Report
CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event
6/6
06:14 pm
tvgn
Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event
Low
Report
Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event
6/6
03:57 pm
tvgn
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2 [Yahoo! Finance]
Medium
Report
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2 [Yahoo! Finance]
6/6
03:52 pm
tvgn
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
High
Report
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
5/29
08:12 am
tvgn
Tevogen Bio Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Medium
Report
Tevogen Bio Reports First Quarter 2024 Financial Results [Yahoo! Finance]
5/29
08:00 am
tvgn
Tevogen Bio Reports First Quarter 2024 Financial Results
Low
Report
Tevogen Bio Reports First Quarter 2024 Financial Results
5/16
02:00 pm
tvgn
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
Low
Report
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
5/10
05:46 pm
tvgn
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives [Yahoo! Finance]
High
Report
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives [Yahoo! Finance]
5/10
05:40 pm
tvgn
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
Medium
Report
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
5/1
08:19 am
tvgn
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives [Yahoo! Finance]
Low
Report
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives [Yahoo! Finance]
5/1
08:05 am
tvgn
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
Low
Report
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
4/26
09:39 am
tvgn
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments [Yahoo! Finance]
Low
Report
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments [Yahoo! Finance]
4/26
09:23 am
tvgn
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
High
Report
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
4/11
08:14 am
tvgn
Tevogen Bio's Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers [Yahoo! Finance]
Medium
Report
Tevogen Bio's Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers [Yahoo! Finance]
4/11
08:05 am
tvgn
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
Low
Report
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
4/3
08:05 am
tvgn
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
High
Report
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
3/28
08:05 am
tvgn
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
Medium
Report
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
3/27
09:32 am
tvgn
Tevogen Bio Announces Series A-1 Preferred Stock Investment [Yahoo! Finance]
High
Report
Tevogen Bio Announces Series A-1 Preferred Stock Investment [Yahoo! Finance]
3/20
07:00 am
tvgn
Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant
Low
Report
Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant